Trackers› Clinical trials› L'Hospitalet de Llobregat

Clinical trial register · Spain

Clinical Trials in L'Hospitalet de Llobregat, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in L'Hospitalet de Llobregat

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Jaén, Málaga, Palma de Mallorca, Salamanca, Barcelona, L'Hospitalet de Llobregat, Valencia, A Coruña

2027-11-23

Not yet open

Timing of Success Evaluation After Flapless Treatment of Peri-Implantitis

NCT07844642Peri-implantitis

University of Barcelona

Observational

L'Hospitalet de Llobregat

2026-10

Not yet open

Air Polishing for Pain and Compliance in Supportive Periodontal Therapy

NCT07837947Periodontitis

Octavi Camps-Font

Not applicable

L'Hospitalet de Llobregat

2026-10

Not yet open

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer

DrugsPorustobart·Keytruda·Pembrolizumab

Solstice Oncology, Inc.

Phase 2

100

Barcelona, L'Hospitalet de Llobregat, Madrid

2026-09-30

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Badalona, Barcelona, Córdoba, Galdakao, Granollers, Hospitalet Llobregat, L'Hospitalet de Llobregat, Madrid

2026-09-17

Not yet open

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786Non Small Cell Lung Cancer, Respiratory Tract Neoplasm

DrugsFecal Microbiota Transplantation·Durvalumab·Paclitaxel·Carboplatin

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Granada, Santiago de Compostela, Lugo

2026-09-15

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca, Valencia

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga

2026-09-08

Not yet open

Patient Perspectives Throughout Peri-Implantitis Treatment

NCT07694323Peri-implantitis

University of Barcelona

Observational

L'Hospitalet de Llobregat

2026-09-03

Recruiting

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471T-cell NHL (PTCL or CTCL)

Kyowa Kirin, Inc.

Phase 1

Badalona, L'Hospitalet de Llobregat, Pamplona, Madrid

2026-09-02

Not yet open

The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Diseases

NCT07663955Frailty, Sarcopenia, Hospital Discharge, Physical Activity

Hospital Universitari de Bellvitge

Not applicable

L'Hospitalet de Llobregat

2026-09-01

Not yet open

Comparison of Anesthetic Efficacy and Safety Between Inferior Alveolar Nerve Block and the Infiltrative Technique for the Treatment of Peri-implant Diseases in Posterior Mandibular Implants

NCT07590037Local Anesthesia, Dental Implants, Periimplantitis

University of Barcelona

Not applicable

L'Hospitalet de Llobregat

2026-09

Not yet open

Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy

NCT07571954Acute Ischemic Stroke

iVascular S.L.U.

Not applicable

Málaga, Zaragoza, Barcelona, L'Hospitalet de Llobregat, Vigo

2026-08-31

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santander, Seville

2026-07-16

Recruiting

CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation)

NCT07755449Locally Advanced Head and Neck Squamous Cell Carcinoma

Institut Català d'Oncologia

Phase 2

101

L'Hospitalet de Llobregat

2026-07-13

Recruiting

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

NCT07690436Transthyretin Amyloid Cardiomyopathy

AstraZeneca

Observational

500

L'Hospitalet de Llobregat, Madrid, Palma de Mallorca

2026-07-08

Recruiting

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

NCT07215364Early-stage Breast Cancer

Spanish Breast Cancer Research Group

Not applicable

L'Hospitalet de Llobregat, Pamplona, Granada, Madrid, Seville

2026-07-02

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

L'Hospitalet de Llobregat, Madrid, Seville

2026-07-02

Recruiting

Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY)

NCT07644624Anterior Shoulder Instability, Shoulder Instability, Shoulder Dislocation

Hospital Universitari de Bellvitge

Not applicable

L'Hospitalet de Llobregat

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2026-06-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia

2026-06-11

Not yet open

BELLRICU PROJECT: Precision Medicine in Respiratory Intermediate Care Units

NCT07644637Acute Respiratory Failure (ARF), Intermediate Respiratory Care Unit, Respiratory Precision Medicine, Mortality Prediction

Hospital Universitari de Bellvitge

Observational

624

L'Hospitalet de Llobregat

2026-06-10

Recruiting

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066Metastatic Hormone-sensitive Prostate Cancer

DrugsApalutamide (Erleada)·Docetaxel

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 3

320

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Santander, Granada, Santiago de Compostela, Madrid, Murcia

2026-06-05

Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934Metastatic Prostate Cancer

DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona

2026-06-03

Not yet open

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

NCT07593040Renal Cell Carcinoma

DrugsLenvatinb·Belzutifan

Vall d'Hebron Institute of Oncology

Phase 2

150

Córdoba, Zaragoza, Santander, Barcelona, L'Hospitalet de Llobregat, Sabadell, Lugo, Ourense

2026-06

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Salamanca, Valencia

2026-05-21

Recruiting

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

NCT07571174Amyotrophic Lateral Sclerosis

DrugLY4256984

Eli Lilly and Company

Phase 1

L'Hospitalet de Llobregat, Valencia

2026-05-14

Recruiting

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07571200Amyotrophic Lateral Sclerosis

DrugLY4256984

Eli Lilly and Company

Phase 1

L'Hospitalet de Llobregat, Valencia

2026-05-14

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña

2026-05-11

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela

2026-05-04

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville, Valencia

2026-05-04

Recruiting

Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients

NCT07551258Intubated ICU Patients, Ventilator Associated Pneumonia ( VAP), Immunoparalysis

Hospital Universitari de Bellvitge

Observational

170

L'Hospitalet de Llobregat

2026-05-01

Recruiting

Home tDCS for the Treatment of Major Depression.

NCT07510880Major Depression Disorder

Ionclinics & Deionic SL

Not applicable

198

L'Hospitalet de Llobregat, Mataró, Sabadell

2026-04-14

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Seville, L'Hospitalet de Llobregat, Madrid, Barcelona, Las Palmas, Valencia

2026-04-09

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

NCT07405801Breast Cancer

DrugsInavolisib·Ribociclib·Fulvestrant

Hoffmann-La Roche

Phase 2

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Valencia

2026-04-07

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab

CatalYm GmbH

Phase 2

104

Zaragoza, L'Hospitalet de Llobregat, Barcelona, Pamplona, Madrid

2026-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470Kidney Transplant Rejection

DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus

Sanofi

Phase 2/3

526

Barcelona, L'Hospitalet de Llobregat, Málaga

2026-03-13

Recruiting

Study on Prostate Salvage Using High-dose-rate Brachytherapy

NCT07860528Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Observational

Benidorm, L'Hospitalet de Llobregat, Santander, Córdoba, San Sebastián, Madrid, Pamplona, Vigo

2026-03-11

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

360

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Lleida, Pozuelo de Alarcón, El Palmar, Vigo, Barakaldo

2026-03-10

Active, closed

Impact of the ARM Technique on the Prevention of Lymphedema After Axillary Lymphadenectomy: A Multicenter Randomized Clinical Trial

NCT07515300Breast Cancer, Lymphedema Arm

Hospital Universitari de Bellvitge

Not applicable

100

L'Hospitalet de Llobregat

2026-03-01

Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

NCT07371585Breast Cancer Stage IV

DrugsPertuzumab·Trastuzumab deruxtecan

SOLTI Breast Cancer Research Group

Phase 2

300

Barcelona, A Coruña, Alicante, Badajoz, Bilbao, Girona, Granada, L'Hospitalet de Llobregat

2026-02-18

Recruiting

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

NCT07361302Acute Ischemic Stroke

DrugTenecteplase

Boehringer Ingelheim

Phase 3

1,325

A Coruña, Alicante, Barakaldo, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca

2026-02-17

Recruiting

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

NCT07624838CD30-Positive Peripheral T-Cell Lymphoma

DrugBrentuximab Vedotin

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Observational

100

A Coruña, Palma de Mallorca, Badalona, Barcelona, L'Hospitalet de Llobregat, Sant Joan Despí, Santander, Jerez de la Frontera

2026-02-15

Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

DrugsNucresiran·Vutrisiran

Alnylam Pharmaceuticals

Phase 3

125

Barcelona, Huelva, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca

2026-02-03

Not yet open

Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)

NCT07368218Pancreatic Cancer

Hospital Universitari de Bellvitge

Not applicable

124

L'Hospitalet de Llobregat

2026-01-31

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Santiago de Compostela, L'Hospitalet de Llobregat, Pamplona, Valencia, Valladolid, Seville

2026-01-25

Recruiting

Comparison of Biportal Versus Multiportal Robotic Approaches for Pulmonary Resection in NSCLC

NCT07818135Non-Small Cell Lung Cancer

Carlos Déniz

Not applicable

L'Hospitalet de Llobregat

2026-01-15

Recruiting

Withdrawal of Heart Failure Treatment Patients With Non-ischemic Cardiomyopathy Who Have Been Super-responders to Cardiac Resynchronization Therapy.

NCT07851779Non-ischemic Cardiomyopathy, Cardiac Resynchronisation Therapy (CRT)

Institut d'Investigació Biomèdica de Bellvitge

Phase 4

L'Hospitalet de Llobregat, Barcelona, Girona, Granada

2026-01-14

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Palma de Mallorca, L'Hospitalet de Llobregat, Majadahonda, Barcelona, Madrid, Santiago de Compostela, Seville, Toledo

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Santiago de Compostela, Elche, Granada, Seville, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Girona

2026-01-06

Recruiting

Effect of Probe Material on Peri-implant Probing

NCT07304752Peri-implant Health, Peri-implant Mucositis

University of Barcelona

Not applicable

L'Hospitalet de Llobregat

2026-01-01

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

A Coruña, Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Girona, L'Hospitalet de Llobregat, Madrid

2025-12-29

Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

NCT07237256Breast Cancer

UNICANCER

Phase 3

3,902

Badajoz, Barcelona, Bilbao, Fuenlabrada, Granada, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-12-18

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Santiago de Compostela, Málaga, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Madrid, Córdoba, Valencia

2025-12-11

Recruiting

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

DrugsAbiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

123

Granada, L'Hospitalet de Llobregat, Barcelona, Madrid

2025-12-05

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Barcelona, L'Hospitalet de Llobregat, Madrid, Santander

2025-12-04

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela, Valencia, Zaragoza

2025-12-03

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid

2025-11-28

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan·Cabozantinib

Merck Sharp & Dohme LLC

Phase 3

904

L'Hospitalet de Llobregat, Santander, Girona, Madrid, Valencia, Barcelona, Córdoba

2025-11-26

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Santander, Oviedo, Alicante, Barcelona, Burgos

2025-11-25

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Albacete, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz, El Palmar

2025-11-11

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca

2025-11-07

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-03

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045Pancreatic Adenocarcinoma Metastatic

DrugsOMTX705·Nab-paclitaxel·Tislelizumab·Gemcitabine

Oncomatryx Biopharma S.L.

Phase 1

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela

2025-10-28

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer

DrugLuxdegalutamide

Novartis Pharmaceuticals

Phase 1/2

188

Santiago Compostela, L'Hospitalet de Llobregat, Madrid

2025-10-15

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2025-10-02

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid

2025-09-30

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590Mantle Cell Lymphoma (MCL)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca

2025-09-30

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Mérida, L'Hospitalet de Llobregat, Jerez de la Frontera, Benalmádena, Cáceres, Málaga, Palma, Seville

2025-09-16

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2025-09-13

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Oviedo, Pamplona, Salamanca, San Carlos

2025-08-31

Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06979596Malignant Neoplasm

DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole

Merck Sharp & Dohme LLC

Phase 2

250

L'Hospitalet de Llobregat, A Coruña, Madrid

2025-08-11

Recruiting

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

NCT07100119ALS (Amyotrophic Lateral Sclerosis)

DrugLY4256984

Eli Lilly and Company

Phase 1

L'Hospitalet de Llobregat, Valencia

2025-08-05

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

Recruiting

Nursing Interventions to Enhance Positive Mental Health and Self Care in Women During the Climacteric

NCT07165964Climacteric Symptoms, Climactericum, Self Care

University of Barcelona

Not applicable

250

L'Hospitalet de Llobregat

2025-07-31

Recruiting

PALACE: Cemiplimab Trial According to ctDNA Levels

NCT06917573Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer

DrugsCarboplatine·Cemiplimab·Paraplatin·Taxol

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, Girona

2025-07-29

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

A Coruña, Badajoz, Barcelona, Cáceres, El Palmar, L'Hospitalet de Llobregat, Lleida, Madrid

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

A Coruña, Elche, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Palma, Madrid, Valencia

2025-07-23

Recruiting

Weight Management in Obese Cancer Patients During Curative Active Treatment

NCT07058207Obesity, Solid Neoplasm, Stage II-IV, Curative Treatment

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

L'Hospitalet de Llobregat

2025-07-22

Active, closed

Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia

NCT07155590Staphylococcal Aureus Infection, Staphylococcus Aureus Bacteraemia

Hospital Universitari de Bellvitge

Observational

369

L'Hospitalet de Llobregat, Seville

2025-07-21

Recruiting

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

NCT07057596Mestastatic Uveal Melanoma

DrugTebentafusp

Grupo Español Multidisciplinar de Melanoma

Phase 2

L'Hospitalet de Llobregat, Madrid, Valencia

2025-07-18

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida

2025-07-02

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

L'Hospitalet de Llobregat, Bilbao, Salamanca, Jaén, Santiago de Compostela, Pozuelo de Alarcón, Valencia, Barcelona

2025-06-30

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña

2025-06-25

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid, Valencia

2025-06-19

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Barcelona, L'Hospitalet de Llobregat, Burgos, Granada, Madrid, Oviedo, Seville, Valencia

2025-06-12

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-06-09

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Barcelona, L'Hospitalet de Llobregat, Granada, Madrid, Seville, Valencia

2025-06-09

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón

2025-06-04

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca

2025-05-30

Active, closed

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373VEXAS, VEXAS Syndrome

DrugPacritinib

Swedish Orphan Biovitrum

Phase 2

156

Barcelona, L'Hospitalet de Llobregat, Salamanca

2025-05-28

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2025-05-28

Recruiting

Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)

NCT07038265Acute Coronary Syndromes (ACS), Cardiac Rehabilitation, Frailty, Women

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

202

L'Hospitalet de Llobregat

2025-05-26

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

L'Hospitalet de Llobregat, Girona, Barcelona, Córdoba, Madrid, Valencia

2025-05-22

Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Madrid

2025-05-13

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Salamanca, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2025-05-06

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

350

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida, Valladolid

2025-05-06

Recruiting

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

NCT06863155Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

500

Albacete, Alicante, Badajoz, Castelló, Ciudad Real, Elche, L'Hospitalet de Llobregat, Laguna

2025-05-06

Recruiting

Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41

NCT07504913Stomach Neoplasms, Validation Study

Parc de Salut Mar

Observational

505

Badalona, Barcelona, L'Hospitalet de Llobregat, Puerto Real, Logroño, Lleida

2025-05-03

Recruiting

Validation of a Questionnaire to Measure Cough Severity

NCT06669897Cough

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

100

Badalona, L'Hospitalet de Llobregat, Sabadell, Barcelona

2025-05-01

By invitation

ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients

NCT07070284Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation

Joan Sabater-Riera

Observational

500

Seville, L'Hospitalet de Llobregat, Barcelona, Sabadell, Donostia / San Sebastian

2025-05-01

Not yet open

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

NCT06852625Kidney Transplant Rejection

Fundacion Clinic per a la Recerca Biomédica

Phase 1

Badalona, Barcelona, L'Hospitalet de Llobregat, Zaragoza

2025-05

By invitation

Effect on Body Weight Reduction of a Behavioral Intervention on Lifestyle Using a Digital Nutritional Program in People Living With HIV and Metabolic Dysfunction-associated Steatotic Liver Disease

NCT07456332Metabolic Dysfunction-Associated Steatotic Liver Disease, People Living With HIV, Life Style

Hospital Universitari de Bellvitge

Not applicable

116

L'Hospitalet de Llobregat

2025-04-23

Recruiting

Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia

NCT06851910Trigeminal Neuralgia

DrugLacosamide

Hospital Universitari de Bellvitge

Observational

L'Hospitalet de Llobregat

2025-04-21

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

L'Hospitalet de Llobregat, Majadhonda, Madrid, Valencia, Barcelona, Málaga

2025-04-15

Recruiting

Impact of IBD Activity on Frailty in Patients Over 60 Years

NCT06844318IBD

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

153

Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa, Mataró, Terrassa, Viladecans, Torrelavega

2025-04-14

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville

2025-04-09

Recruiting

Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate

NCT06649357Prostate Hyperplasia, Surgery, Endoscopic Anatomical Enucleation of the Prostate (EEAP)

Fundacio Puigvert

Not applicable

130

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Santander, Gijón, Valladolid

2025-04-01

Not yet open

Oscillometry in the COPD Exacerbator Phenotype With Triple Inhaled Therapy Study

NCT06931899COPD (Chronic Obstructive Pulmonary Disease)

Hospital Universitari de Bellvitge

Observational

L'Hospitalet de Llobregat

2025-04

Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907Non-small Cell Lung Cancer

DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-03-30

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

A Coruña, Córdoba, Donostia / San Sebastian, El Palmar, L'Hospitalet de Llobregat, Madrid, Palma de Mallorca, Valencia

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona

2025-03-27

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga

2025-03-25

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Seville, L'Hospitalet de Llobregat, Madrid, Valencia, Barcelona

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)

2025-03-14

Active, closed

EucaLimus Post-Market Registry

NCT06621524Coronary Arterioscleroses

OrbusNeich

Observational

251

L'Hospitalet de Llobregat, Barcelona, Córdoba, Lugo, San Cristóbal de La Laguna, Tarragona

2025-03-14

Active, closed

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462Ophthalmic Safety in Patients With Breast Cancer

AstraZeneca

Observational

160

Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Leganés, Madrid, Majadahonda, Salamanca

2025-03-05

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona

2025-03-03

Active, closed

Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure

NCT07178483Acute Hypoxemic Respiratory Failure, Non Invasive Ventilation (NIV), Bioimpedance Measurement Capacity, Calorimetry, Indirect

Hospital Universitari de Bellvitge

Observational

500

L'Hospitalet de Llobregat

2025-03-01

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Eixample, L'Hospitalet de Llobregat, Madrid, Barcelona, Málaga

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia

2025-02-27

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-02-13

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Barcelona, Santander, L'Hospitalet de Llobregat, Pamplona, Madrid

2025-02-06

Recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

NCT06431633Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma

DrugsZimberelimab·Sacituzumab Govitecan·Paraplatin·Cisplatin

Fundación GECP

Phase 3

129

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, A Coruña

2025-02-04

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Córdoba, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Seville, Valencia

2025-01-29

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Seville, L'Hospitalet de Llobregat, Barakaldo, Las Palmas de Gran Canaria, Majadahonda, Gijón, Alicante, Barcelona

2025-01-27

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville

2025-01-21

Active, closed

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

NCT06133517Urothelial Bladder Carcinoma

DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan

Fundación para el Progreso de la Oncología en Cantabria

Phase 2

L'Hospitalet de Llobregat, Santander, Madrid, Pamplona, Toledo, Valladolid

2025-01-20

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib

Pfizer

Phase 3

1,035

A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Eixample, Bilbao, Jerez de la Frontera

2025-01-06

Recruiting

Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis

NCT06955221Endometrioma, Ultrasound Therapy; Complications, Quality of Life, Pelvic Pain

Hospital Universitari de Bellvitge

Not applicable

288

Palma de Mallorca, Badalona, Igualada, L'Hospitalet de Llobregat, Martorell, Sabadell, Sant Boi de Llobregat, Viladecans

2025-01-01

Active, closed

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

NCT06746116Advanced or Recurrent Endometrial Cancer

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Alicante, Barakaldo, Barcelona, Córdoba, El Palmar, Girona, L'Hospitalet de Llobregat

2024-12-30

Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384Triple-negative Breast Cancer

DrugsTaxol·Keytruda·Paclitaxel·Pembrolizumab

UNICANCER

Phase 2

354

Alicante, Badalona, Barcelona, El Palmar, Granada, L'Hospitalet de Llobregat, León, Lleida

2024-12-27

Recruiting

Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem

NCT07039994Non-Small Cell Lung Cancer

Jesús González

Not applicable

200

Badalona, L'Hospitalet de Llobregat

2024-12-24

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga

2024-12-24

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

A Coruña, Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Úbeda, Lugo, Madrid, Majadahonda

2024-12-19

Recruiting

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT06657833Coronary Artery Disease

Fundación EPIC

Not applicable

128

Barcelona, Fuencarral-El Pardo, Galdakao, L'Hospitalet de Llobregat, León, Madrid, Moncloa-Aravaca, Pamplona

2024-12-17

Active, closed

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

NCT06668558Acute Myeloid Leukemia

DrugsAzacitidine·Venetoclax

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Phase 2

Palma de Mallorca, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Lleida, Tarragona, Terrassa

2024-12-16

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

Málaga, L'Hospitalet de Llobregat, Madrid

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

L'Hospitalet de Llobregat, Sant Andreu de la Barca, Madrid, Seville, Zaragoza

2024-12-09

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barakaldo, A Coruña, Las Palmas de Gran Canaria, Majadahonda, Marbella

2024-12-03

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Barcelona, Córdoba, Getafe, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-12-02

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·B/F/TAF·Cabotegravir

ViiV Healthcare

Phase 3

326

L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia

2024-12-02

Recruiting

Evaluation of heepSync, a Novel Algorithm for Transcutaneous Electrical Stimulation of Respiratory Muscles in Mechanically Ventilated Patients.

NCT07363902Ventilator-induced Diaphragm Dysfunction, VIDD, Weaning Failure

Tesai Care SL

Not applicable

Barcelona, L'Hospitalet de Llobregat, Sabadell

2024-12-01

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid

2024-11-26

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

L'Hospitalet de Llobregat, Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Marbella, Pamplona, Alicante

2024-11-25

Recruiting

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

NCT07254754DIFFUSE LARGE B-CELL LYMPHOMA

DrugAxicabtagene Ciloleucel

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria

2024-11-20

Recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149Uveal Melanoma

DrugTebentafusp

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

290

L'Hospitalet de Llobregat, Valladolid

2024-11-11

Active, closed

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT06659640Hereditary Hemorrhagic Telangiectasia

DrugALN-6400

Alnylam Pharmaceuticals

Phase 1/2

L'Hospitalet de Llobregat

2024-11-07

Active, closed

Comparison of Anesthetic Efficacy and Safety Between Nerve Block and Infiltrative Technique for Mandibular Posterior Implant Placement.

NCT06641232Dental Implants, Local Anesthesia

University of Barcelona

Not applicable

L'Hospitalet de Llobregat

2024-11-05

Active, closed

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

NCT06695832Staphylococcus Aureus Bacteremia

Hospital Universitari de Bellvitge

Observational

369

L'Hospitalet de Llobregat, Badalona, Barcelona

2024-11-01

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Córdoba, L'Hospitalet de Llobregat, Terrassa, Burjassot, Barcelona, Seville, Valencia, Zaragoza

2024-10-30

Recruiting

Study of Tacrolimus Melt-Dose® for Lung Transplant Patients

NCT07042035Lung Trasplant, Lung Transplantation

Chiesi España, S.A.U.

Observational

240

L'Hospitalet de Llobregat, Madrid

2024-10-29

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

L'Hospitalet de Llobregat, Madrid, Valencia

2024-10-22

Active, closed

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563Lymphoma, Non-Hodgkin

DrugsJNJ-75348780·JNJ-80948543

Janssen Research & Development, LLC

Phase 1

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

L'Hospitalet de Llobregat, Barcelona, Madrid, Manresa, Valencia

2024-10-21

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

A Coruña, L'Hospitalet de Llobregat, Madrid, Murcia, Pozuelo de Alarcón, Valencia

2024-10-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia

2024-10-17

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer

Fundacio Clinic Barcelona

Not applicable

304

L'Hospitalet de Llobregat, Granada, Santiago de Compostela, León, Madrid, Murcia, Reus, Bilbao

2024-10-11

Recruiting

Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry

NCT06620757Atrial Fibrillation

Fundación EPIC

Observational

234

A Coruña, Aravaca, Barcelona, Córdoba, Fuencarral-El Pardo, Gijón, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2024-10-10

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Active, closed

SIRAKI 02 Posthoc Analysis.

NCT06781294Cardiac Surgery Requiring Cardiopulmonary Bypass, Acute Kidney Injury, Chronic Kidney Disease(CKD), Kidney Failure, Acute

Hospital Universitari de Bellvitge

Not applicable

343

L'Hospitalet de Llobregat

2024-10-01

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-23

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-09-18

Recruiting

EEAP Using Moses 2.0 Technology vs the Thulium Fiber Laser in Medium-Large Prostates

NCT06565741Prostatic Hyperplasia, Surgery, Endoscopic Anatomical Enucleation of the Prostate (EEAP)

Fundacio Puigvert

Not applicable

120

Barcelona, L'Hospitalet de Llobregat

2024-09-03

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

L'Hospitalet de Llobregat, Barcelona, Madrid

2024-08-14

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

NCT06379217Metastatic Neuroendocrine Prostate Cancer

Drugs[68Ga]Ga-PSMA-11·[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Ga-NeoB

Novartis Pharmaceuticals

Phase 1

L'Hospitalet de Llobregat, Madrid

2024-07-29

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Córdoba

2024-07-24

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo

2024-07-22

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy

NCT06474819Complete Heart Block, Second Degree Atrioventricular Block Möbitz Type II

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

326

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-07-12

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2024-07-09

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca

2024-06-29

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Recruiting

Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations

NCT07148154Endometrial Cancer

MiMARK Diagnostics, S.L.

Observational

3,000

L'Hospitalet de Llobregat, Barcelona

2024-06-24

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Sabadell, Valladolid

2024-06-20

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Recruiting

Reversibility of Cardiac Conduction Disturbances Following TAVI

NCT06481137Aortic Stenosis, Transcatheter Aortic Valve Implantation, Conduction Disturbances

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

209

L'Hospitalet de Llobregat

2024-06-17

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga

2024-05-21

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

L'Hospitalet de Llobregat, Madrid, Barcelona

2024-05-20

Recruiting

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

NCT07717268Prostatic Neoplasms, Castration-Resistant

DrugsZytiga·Xtandi

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 2

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Bilbao, Salamanca, Valladolid, Terrassa, Santiago de Compostela

2024-05-16

Recruiting

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205Richter Syndrome

DrugMosunetuzumab

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

Phase 2

Barcelona, L'Hospitalet de Llobregat, Santander, Las Palmas de Gran Canaria, Madrid, Murcia, Marbella, Oviedo

2024-05-15

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

DrugsGa-NeoB·Lu-NeoB

Novartis Pharmaceuticals

Phase 1

Granada, Badalona, L'Hospitalet de Llobregat, Madrid

2024-05-15

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid

2024-05-06

Not yet open

EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)

NCT06375954Malignant Biliary Obstruction, Pancreatic Cancer, Biliary Tract Neoplasms

Hospital Universitari de Bellvitge

Not applicable

L'Hospitalet de Llobregat

2024-05-01

Active, closed

Dimethyl Fumarate in Adrenomyeloneuropathy

NCT06513533Adrenomyeloneuropathy Without Cerebral Involvement

DrugDimethyl Fumarate

Pujol, Aurora, M.D.

Phase 2/3

L'Hospitalet de Llobregat, Donostia / San Sebastian, Madrid

2024-04-23

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt

2024-04-16

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

300

Barcelona, L'Hospitalet de Llobregat

2024-04-11

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438Non-Small Cell Lung Cancer

DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

840

Santiago de Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

L'Hospitalet de Llobregat, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Barcelona, Madrid

2024-04-03

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca

2024-03-29

Recruiting

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer

Voronoi, Inc

Phase 1/2

315

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga

2024-03-26

Recruiting

Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

NCT05914441Purpura, Thrombocytopenic

Fundación Española de Hematología y Hemoterapía

Observational

300

Seville, L'Hospitalet de Llobregat, Barcelona, Guadalajara, Madrid, Murcia, Valencia

2024-03-22

Active, closed

Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

NCT06214819Coronary Artery Disease

Fundación EPIC

Not applicable

Barcelona, Girona, L'Hospitalet de Llobregat

2024-03-20

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Badalona, L'Hospitalet de Llobregat, Madrid

2024-03-15

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Granada, L'Hospitalet de Llobregat, Barcelona, El Palmar, Madrid, Seville, Valencia

2024-03-12

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent

Instituto de Investigación Biomédica de Salamanca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville

2024-03-11

Active, closed

PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

NCT06321757Coronary Artery Disease

Fundación EPIC

Observational

501

Albacete, Alicante, Barakaldo, Boadilla del Monte, Ciudad Real, Granada, Huelva, L'Hospitalet de Llobregat

2024-02-26

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza

2024-02-22

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-02-17

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Badalona, Barcelona, Elche, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia

2024-02-05

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca

2024-02-05

Active, closed

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820Pompe Disease (Late-onset)

Astellas Gene Therapies

Not applicable

119

Albacete, Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Valencia

2024-02-01

Recruiting

Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication

NCT06049654Aortic Valve Stenosis, Structural Valve Deterioration

Fundación EPIC

Not applicable

104

L'Hospitalet de Llobregat, Madrid, Majadahonda, Salamanca, Valencia

2024-02-01

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

L'Hospitalet de Llobregat, Madrid

2024-01-23

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

NCT06143878Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

774

Alicante, Barakaldo, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia

2024-01-17

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,181

A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-01-11

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

NCT06174987Advanced Cancer, Metastatic Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

A Coruña, Barcelona, Distrito de Les Corts, L'Hospitalet de Llobregat, Madrid

2024-01-05

Active, closed

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298Prostatic Neoplasm

DrugsARPI·Pylarify·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid

2024-01-03

Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache

Hospital Universitari Vall d'Hebron Research Institute

Observational

700

Badalona, Barcelona, L'Hospitalet de Llobregat, Mollet del Vallès, Viladecans, Albacete, Madrid, Zaragoza

2024-01-02

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Santiago de Compostela, Palma, L'Hospitalet de Llobregat, Santander, Pozuelo de Alarcón, Oviedo, Barcelona, Granada

2023-12-28

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Murcia, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Donostia / San Sebastian, Girona, Las Palmas de Gran Canaria, Lleida

2023-12-27

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

220

Alicante, Barakaldo, El Palmar, Girona, Granada, L'Hospitalet de Llobregat, Lleida, Madrid

2023-12-15

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

L'Hospitalet de Llobregat, Sabadell, Santander, Majadahonda, Oviedo, Barcelona, Cadiz, Girona

2023-12-11

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Barcelona, Córdoba

2023-12-06

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

L'Hospitalet de Llobregat, Pozuelo de Alarcón, Majadahonda, Málaga, Barcelona, Seville

2023-12-06

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Recruiting

Safety And Performance Of Disc Care To Prevent Lumbar Disc Herniation Recurrence

NCT06023719Disc Herniation, Disk Herniated Lumbar

NEOS Surgery

Not applicable

L'Hospitalet de Llobregat, Madrid, Barcelona, San Cristóbal de La Laguna

2023-11-30

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Oviedo, Pamplona, San Sebastián

2023-11-29

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

NCT05948943Lymphatic Malformations

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2/3

232

Palma, Esplugues, L'Hospitalet de Llobregat, A Coruña, Barcelona, Madrid

2023-11-24

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Sabadell, Valencia

2023-11-21

Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma

DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

914

L'Hospitalet de Llobregat, Barcelona, Esplugues de Llobregat, Madrid

2023-11-20

Active, closed

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

NCT05784012Head and Neck Squamous Cell Carcinoma

DrugsNiraparib·Dostarlimab·Cisplatin

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia

2023-11-13

Active, closed

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1

L'Hospitalet de Llobregat, Barcelona, Madrid

2023-11-13

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Burgos, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santa Cruz de Tenerife

2023-11-11

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza

2023-11-08

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Girona, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Seville, Valencia

2023-11-07

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

L'Hospitalet de Llobregat, Majadahonda, El Palmar, Madrid, Málaga, Seville, Valencia

2023-11-07

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville, Valencia

2023-10-31

Active, closed

Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia

NCT06787326Haematological Malignancy, Febrile Neutropenia, Blood Stream Infection

Hospital Universitari de Bellvitge

Observational

228

L'Hospitalet de Llobregat

2023-10-27

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms

Drugs177Lu-edotreotide·Everolimus

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

170

Seville, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Oviedo, Valencia, Barcelona

2023-10-27

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Barcelona, L'Hospitalet de Llobregat, Valencia, Granada, Madrid, Oviedo, Salamanca, Seville

2023-10-24

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

L'Hospitalet de Llobregat, Fuenlabrada, Barcelona, Córdoba, Madrid, Valencia

2023-10-11

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Torrevieja, Córdoba, Málaga, Seville, Calella, Barcelona, Centelles, L'Hospitalet de Llobregat

2023-10-09

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville

2023-10-09

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia

2023-10-05

Active, closed

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

NCT05888493Follicular Lymphoma (FL)

DrugTisagenlecleucel

Novartis Pharmaceuticals

Phase 3

109

Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca

2023-10-02

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Badalona, L'Hospitalet de Llobregat, Barakaldo, Santander, Majadahonda, Badajoz, Barcelona, L'Hospitaler de Llobregat

2023-09-22

Active, closed

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

NCT05846230Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 2

268

Barcelona, L'Hospitalet de Llobregat, Mérida, Pozuelo de Alarcón

2023-09-08

Recruiting

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

NCT06055504Non-ischemic Dilated Cardiomyopathy

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Not applicable

900

Santiago de Compostela, L'Hospitalet de Llobregat, Sabadell, A Coruña, Majadahonda, Oviedo, Alicante, Barcelona

2023-09-06

Active, closed

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

NCT06059001Metastatic Pancreatic Cancer

DrugsOMO-103·Nab-paclitaxel·Gemcitabine

Peptomyc S.L.

Phase 1

Barcelona, L'Hospitalet de Llobregat, Santander, Madrid, Málaga, Zaragoza

2023-08-31

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

L'Hospitalet de Llobregat, Sabadell, Majadahonda, Barcelona, Madrid, Valencia

2023-08-14

Active, closed

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

L'Hospitalet de Llobregat, Madrid, Barcelona, Seville

2023-07-06

By invitation

Diabetes Remission and Hypoabsorptive Bariatric Surgery

NCT06043245Severe Obesity, Diabetes Mellitus, Type 2, Bariatric Surgery Candidate

Hospital Universitari de Bellvitge

Not applicable

L'Hospitalet de Llobregat

2023-06-21

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

L'Hospitalet de Llobregat, Majadahonda, Manises, Barcelona, Granada, Madrid, Valencia

2023-06-21

Active, closed

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

NCT05673187NSCLC Stage IV, KRAS P.G12C

DrugAdagrasib

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valencia

2023-06-12

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Majadahonda, El Palmar, Vigo, Huelva, Madrid

2023-06-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia

2023-06-07

Recruiting

IMR-Heart Trasplant Study

NCT06656065Heart Transplant Rejection, Microvascular Resistance

Hospital Miguel Servet

Observational

100

L'Hospitalet de Llobregat, Zaragoza

2023-05-23

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Málaga, Palma de Mallorca, Santiago de Compostela

2023-05-18

Recruiting

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High

University Health Network, Toronto

Not applicable

6,250

Ciutat Vella, Horta-Guinardó, L'Hospitalet de Llobregat, Sabadell, Girona, Santa Cruz de Tenerife

2023-04-30

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

L'Hospitalet de Llobregat, Barcelona, Madrid

2023-04-04

Active, closed

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases

Fundación EPIC

Observational

585

A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo

2023-04-04

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Badalona, Jerez de la Frontera, L'Hospitalet de Llobregat, León, Madrid, Murcia, Oviedo, Palma de Mallorca

2023-03-29

Active, closed

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973Non Small Cell Lung Cancer

DrugsLazertinib·Zirabev·Amivantamab

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valladolid

2023-03-27

Active, closed

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202Bladder Cancer

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 3

1,135

A Coruña, Algeciras, Barcelona, Cadiz, Castellon, L'Hospitalet de Llobregat, Lugo, Madrid

2023-03-23

Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Observational

1,650

L'Hospitalet de Llobregat, Barcelona

2023-03-21

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Lleida, Seville, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2023-03-20

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid

2023-03-15

Recruiting

Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

NCT05781217Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 3

534

L'Hospitalet de Llobregat, Fuenlabrada, Pozuelo de Alarcón, Barakaldo, Barcelona, Madrid, Tarragona, Valencia

2023-03-14

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

A Coruña, Elche, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Donostia / San Sebastian, Lleida

2023-03-03

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Madrid, El Palmar, Pamplona, Valencia

2023-02-08

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

NCT05982093Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer

DrugsElacestrant·Tamoxifen

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Vilanova, El Palmar, Badajoz, Barcelona, Cáceres, Madrid

2023-02-03

Recruiting

Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units

NCT05686850Post Extubation Respiratory Failure

Poitiers University Hospital

Not applicable

670

Barcelona, L'Hospitalet de Llobregat, Oviedo, Toledo

2023-02-02

Active, closed

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

NCT05599061Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Fundación EPIC

Not applicable

609

L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon

2023-01-30

Recruiting

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction

NCT05038462Fetal Growth Retardation, Intrauterine Growth Restriction

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Not applicable

304

Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat

2023-01-18

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Barcelona, Elche(Alicante), L'Hospitalet de Llobregat, Madrid, Santander

2023-01-16

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Alcorcón, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón

2022-12-15

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat

2022-12-14

Recruiting

Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.

NCT04330846Crohn Disease

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Not applicable

Badalona, L'Hospitalet de Llobregat, Manresa, Sabadell, Sant Joan Despí, Terrassa, Cáceres, Girona

2022-11-29

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Badalona (Barcelona), Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-11-21

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Palma de Mallorca, Granollers, L'Hospitalet de Llobregat, Ferrol, Santiago de Compostela, Logroño, Las Palmas de Gran Canaria, Marbella

2022-11-21

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga

2022-10-27

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

L'Hospitalet de Llobregat, Valencia, Barcelona, Madrid, Salamanca

2022-10-26

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

L'Hospitalet de Llobregat, Barcelona, San Cristóbal de La Laguna, Alicante, Córdoba, Lleida, Madrid, Málaga

2022-10-24

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Seville

2022-10-20

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Barcelona, L'Hospitalet de Llobregat, Santiago de Compostela, San Sebastián, Madrid, Pamplona

2022-10-20

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma

DrugsTecentriq·Atezolizumab·Keytruda·Pembrolizumab

Genentech, Inc.

Phase 1

165

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2022-10-20

Recruiting

Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function

NCT05573828Iatrogenic Hypocalcemia

Hospital Universitari de Bellvitge

Not applicable

394

L'Hospitalet de Llobregat

2022-10-11

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

NCT05334706Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18

Miquel Angel Pavon Ribas

Phase 4

L'Hospitalet de Llobregat

2022-09-13

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Santiago de Compostela, Palma de Mallorca, L'Hospitalet de Llobregat, Málaga, Oviedo, Barcelona, Granada, Madrid

2022-09-06

Active, closed

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

NCT05252988Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive

DrugsColesevelam·Loperamide·Neratinib

Spanish Breast Cancer Research Group

Phase 2

177

Elche, Málaga, Zaragoza, L'Hospitalet de Llobregat, Manresa, Mataró, Castellon, Valladolid

2022-08-31

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville

2022-08-30

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

NCT05494606Ulcerative Colitis

AbbVie

Observational

785

L'Hospitalet de Llobregat, Sabadell, Las Palmas de Gran Canaria, Gijón, San Cristóbal de La Laguna, Seville, Galdakao, Almería

2022-08-15

Active, closed

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030Colorectal Cancer

DrugsM9140·Folinic acid·Adrucil·Capecitabine

EMD Serono Research & Development Institute, Inc.

Phase 1

220

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2022-08-04

Active, closed

Transanal Irrigation for Low Anterior Resection Syndrome.

NCT05245331Low Anterior Resection Syndrome

Hospital Universitari de Bellvitge

Not applicable

Barcelona, L'Hospitalet de Llobregat

2022-08-04

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville

2022-07-22

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

Palma de Mallorca, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Seville, Valencia

2022-07-19

Active, closed

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446Metastatic Colorectal Cancer

DrugsEncorafenib·Erbitux·Cetuximab·Keytruda

Pfizer

Phase 2

108

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia, Zaragoza

2022-07-11

Active, closed

The Left Bundle Cardiac Resynchronization Therapy Trial

NCT05434962Left Bundle-Branch Block, Heart Failure, Impaired Left Ventricular Function

Óscar Cano Pérez

Not applicable

176

Alicante, L'Hospitalet de Llobregat, Granada, Huelva, Madrid, Majadahonda, Murcia, Valencia

2022-06-27

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry.

NCT05128604Endoscopic Surgical Procedure, Safety, Training

Hospital Universitari de Bellvitge

Observational

Badalona, L'Hospitalet de Llobregat, Terrassa, Barcelona, Girona

2022-05-23

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca

2022-05-03

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Majadahonda, Bilbao, Barcelona, Madrid, Málaga

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Badalona, L'Hospitalet de Llobregat, El Palmar, Barcelona, Córdoba, Madrid, Málaga, Valencia

2022-05-02

Active, closed

Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia

NCT05210439Bloodstream Infection

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 4

306

Palma de Mallorca, L'Hospitalet de Llobregat, Sabadell, Barakaldo, Jerez de la Frontera, Puerto Real, Donostia / San Sebastian, Logroño

2022-04-28

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Pamplona, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2022-04-26

Active, closed

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

NCT05193019Ischemic Heart Disease, Acute Coronary Syndrome

Fundación EPIC

Observational

717

L'Hospitalet de Llobregat, Barakaldo, Galdakao, Gijón, León, Madrid, Pamplona, Salamanca

2022-03-14

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Badalona, Burgos, Cadiz, Granada, L'Hospitalet de Llobregat, León, Madrid, Majadahonda

2022-03-10

Active, closed

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470Extensive-stage Small-cell Lung Cancer

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 2

187

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2022-03-09

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2022-02-03

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Santiago de Compostela, L'Hospitalet de Llobregat, Córdoba, Las Palmas de Gran Canaria, Majadahonda, Barcelona, Madrid

2022-01-13

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville

2022-01-11

Active, closed

Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III

NCT07821333Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell

DrugsFolfoxiri·Folfox

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 2

L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Valencia

2022-01-01

Active, closed

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627Relapsed Multiple Myeloma

DrugsBelantamab mafodotin·Carfilzomib·Dexamethasone

PETHEMA Foundation

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Palma de Mallorca, Pamplona

2021-12-20

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz

2021-12-13

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487Stage IIIA Non-small Cell Lung Cancer

DrugsParaplatin·Cisplatin·Carboplatin

Fundación GECP

Observational

150

A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona

2021-12-10

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2021-12-07

Active, closed

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

NCT03496883Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

860

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida

2021-12-03

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Sabadell, Pamplona, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga

2021-12-02

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Málaga, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Valencia, Madrid

2021-12-01

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Ferrol, Santiago Compostela, Seville, Mallorca, Palma, el Prat de Llobregat, L'Hospitalet de Llobregat, Sabadell

2021-11-23

Active, closed

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

NCT05012254Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer

DrugsYervoy·Paraplatin·Taxol·Ipilimumab

Fundación GECP

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León

2021-11-18

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Badalona, Barcelona, L'Hospitalet de Llobregat, Terrassa, Granada, Huelva, Jaén, Logroño

2021-11-17

By invitation

Prosthetic Rehabilitation and Its Influence on Masticatory Performance and QoL in Patients Treated for HNC

NCT06124222Quality of Life, Objective Masticatory Performance, Subjective Masticatory Performance, Oral Health

University of Barcelona

Not applicable

L'Hospitalet de Llobregat

2021-11-17

Recruiting

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

NCT04924868Acute Pancreatitis Due to Gallstones

DrugUrsodeoxycholic Acid

Hospital General Universitario de Alicante

Phase 3

332

Santiago de Compostela, Alicante, Elche, Barcelona, L'Hospitalet de Llobregat, Sabadell, Santander, Granada

2021-11-10

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia

2021-11-02

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-10-28

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-10-25

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2021-10-18

Active, closed

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

NCT05011123Yellow Fever

DrugYellow fever vaccine

Sanofi Pasteur, a Sanofi Company

Phase 2

690

Barcelona, L'Hospitalet de Llobregat, Madrid

2021-10-07

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Barcelona, L'Hospitalet de Llobregat, Madrid, Seville

2021-09-29

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville

2021-08-19

Active, closed

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817Small Cell Lung Carcinoma

DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd

Merck Sharp & Dohme LLC

Phase 1/2

110

L'Hospitalet de Llobregat, Barcelona

2021-08-19

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville

2021-08-05

Active, closed

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

NCT04733118Early Breast Cancer

MedSIR

Phase 2

393

L'Hospitalet de Llobregat, Córdoba, Reus, A Coruña, Alicante, Badalona, Barcelona, Bilbao

2021-08-05

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

L'Hospitalet de Llobregat, San Cugat Del Valles, Majadahonda, Pamplona, Oviedo, Barcelona, Córdoba, Madrid

2021-07-14

Active, closed

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2021-07-02

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

A Coruña, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Sant Joan Despí

2021-06-30

Active, closed

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248Primary Membranous Nephropathy

DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone

Hoffmann-La Roche

Phase 3

142

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2021-06-25

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga

2021-06-15

Recruiting

ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

NCT04889924Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection

Hospital Universitari de Bellvitge

Not applicable

820

Badalona, Calella, Granollers, L'Hospitalet de Llobregat, Manresa, Mataró, Sant Cugat del Vallès, Terrassa

2021-06-11

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

L'Hospitalet de Llobregat, Sabadell, Majadahonda, El Palmar, Barcelona, Madrid, Valencia

2021-06-09

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-05-18

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Elche, Badalona, L'Hospitalet de Llobregat, Manresa, Lugo, Majadahonda, Pamplona, Oviedo

2021-05-12

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Sociedad Española de Medicina Nuclear e Imagen Molecular

Observational

5,000

Santiago de Compostela, Granada, Palma de Mallorca, L'Hospitalet de Llobregat, Getafe, Majadahonda, El Palmar, Pamplona

2021-05-10

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Cisplatin/Carboplatin·Fluorouracil·Keytruda

ALX Oncology Inc.

Phase 2

172

Barcelona, Badalona, L'Hospitalet de Llobregat, Leganés, Madrid, Málaga, Pamplona

2021-05-10

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

DrugPhase 2

enGene, Inc.

Phase 1/2

350

Barbera Del Valles, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Santander

2021-04-22

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

A Coruña, Alicante, Badalona, Barcelona, Burgos, Gijón, L'Hospitalet de Llobregat, Madrid

2021-04-15

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Málaga, Barcelona, L'Hospitalet de Llobregat, Pamplona, Palma de Mallorca, Madrid, Valencia

2021-04-08

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

L'Hospitalet de Llobregat, Salamanca, A Coruña, Alicante, Barcelona, Madrid

2021-04-05

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

L'Hospitalet de Llobregat, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Madrid, Málaga, Seville

2021-03-17

Active, closed

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

NCT04759248Breast Cancer

DrugsVinorelbine·Trastuzumab·Atezolizumab

SOLTI Breast Cancer Research Group

Phase 2

Granada, Barcelona, L'Hospitalet de Llobregat, Santa Cruz de Tenerife, A Coruña, Alicante, Cáceres, León

2021-03-15

By invitation

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

NCT04646187Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative

DrugsRemsima·Humira·Infliximab·Adalimumab

University Medical Center Groningen

Phase 4

148

L'Hospitalet de Llobregat

2021-03-11

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

L'Hospitalet de Llobregat, Toledo, Santiago de Compostela, Pozuelo de Alarcón, Madrid, Albacete, Barcelona, Cáceres

2021-03-09

Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

NCT04777994Advanced Solid Tumor Cancer

Calico Life Sciences LLC

Phase 1

248

L'Hospitalet de Llobregat, Madrid

2021-03-09

Active, closed

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung

DrugsTNO155·Opnurasib·Tislelizumab

Novartis Pharmaceuticals

Phase 1/2

344

Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia

2021-02-24

Active, closed

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081Acute Myeloid Leukemia

DrugsDecitabine·Venclexta·Venetoclax

Taiho Oncology, Inc.

Phase 1/2

101

Oviedo, L'Hospitalet de Llobregat, Pamplona, Madrid, Salamanca, Valencia

2021-02-09

Recruiting

TAD After Chemotherapy in Locally Advanced Breast Cancer

NCT05763641Sentinel Lymph Node, Breast Cancer, Locally Advanced

Hospital Universitari de Bellvitge

Observational

162

L'Hospitalet de Llobregat, Barcelona

2021-02-01

Recruiting

Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.

NCT04735198Midgut Carcinoid Tumor, Biliary Stones

Hospital Universitari de Bellvitge

Not applicable

100

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid

2021-01-20

Active, closed

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

NCT04564157Non-Small Cell Lung Cancer, Adjuvant Chemotherapy

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 3

210

Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Cáceres, El Palmar, Girona

2021-01-13

Active, closed

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms

DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

217

L'Hospitalet de Llobregat, Barcelona, Valencia

2021-01-11

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona

2021-01-04

Recruiting

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

NCT06339658Breast Cancer, Axillary Metastases

Hospital Universitari de Bellvitge

Observational

L'Hospitalet de Llobregat

2021-01-01

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

Barcelona, L'Hospitalet de Llobregat, Madrid, Seville

2020-12-28

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid

2020-12-22

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Barcelona, Madrid, Seville, Valencia, Zaragoza

2020-12-21

Active, closed

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1/2

228

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander

2020-12-15

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Málaga, Seville

2020-12-08

Recruiting

Sarcopenia in Colorectal Cancer Patients, Intervention Study

NCT05491434Sarcopenia, Postoperative Complications, Infection;Post Surg Procedure

Hospital Universitari de Bellvitge

Not applicable

370

L'Hospitalet de Llobregat

2020-12-01

Active, closed

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

NCT04127110Non Small Cell Lung Cancer

DrugLorlatinib

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid, Palma de Mallorca, Pamplona, Seville

2020-11-17

Recruiting

Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .

NCT04652180Esophageal Cancer, Esophageal Carcinoma, Postoperative Complications

Hospital Universitari de Bellvitge

Not applicable

108

L'Hospitalet de Llobregat

2020-11-06

Recruiting

A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)

NCT05101382Colorectal Cancer

IFOM ETS - The AIRC Institute of Molecular Oncology

Observational

500

L'Hospitalet de Llobregat, Barcelona, Valencia

2020-10-28

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

L'Hospitalet de Llobregat, Donostia / San Sebastian, Pozuelo de Alarcón, A Coruña, Barcelona, Madrid, Seville, Valencia

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Alcalá de Henares, Badalona, Barcelona, Gijón, L'Hospitalet de Llobregat, Madrid, Palma, Pamplona

2020-10-08

Recruiting

Impact of Systematic Shaving on Margins

NCT05782686Margin, Tumor-Free, Breast Cancer, Surgery

Hospital Universitari de Bellvitge

Not applicable

234

L'Hospitalet de Llobregat

2020-10-07

Active, closed

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

NCT04293393Early Breast Cancer

DrugsLeuprolide·Goserelin·Pegylated liposomal doxorubicin·Abemaciclib

Spanish Breast Cancer Research Group

Phase 2

200

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Castellon, San Sebastián, Vigo, A Coruña, Alicante

2020-10-02

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Ferrol, Santiago de Compostela, Badalona, L'Hospitalet de Llobregat, Fuenlabrada, Majadahonda, Oviedo, Alicante

2020-09-30

Active, closed

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma

DrugsOregovomab·Paraplatin·Taxol·Paclitaxel

CanariaBio Inc.

Phase 3

615

Barcelona, L'Hospitalet de Llobregat, Valencia

2020-08-25

Active, closed

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283Diffuse Large B-cell Lymphoma

DrugsBrentuximab Vedotin·Lenalidomide·Rituximab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

239

L'Hospitalet de Llobregat, Cáceres, Pozuelo de Alarcón, Marbella, Pamplona, Barcelona, Madrid, Pozuelo de Alarcon (madrid)

2020-08-20

Active, closed

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700B-Cell Malignancies

DrugsItacitinib·Parsaclisib·Ibrutinib·Ruxolitinib

Incyte Corporation

Phase 2

112

Alicante, Badalona, Barcelona, Boadilla del Monte, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Salamanca

2020-08-03

Active, closed

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178Advanced HER2+Breast Cancer

DrugsAlpelisib·Pertuzumab·Trastuzumab

Novartis Pharmaceuticals

Phase 3

L'Hospitalet de Llobregat

2020-07-16

Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia

DrugsVenclexta·Azacitidine·Venetoclax

Taiho Oncology, Inc.

Phase 2/3

316

Badalona, L'Hospitalet de Llobregat, Pamplona, Oviedo, Barcelona, Cáceres, Girona, Granada

2020-05-21

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185Urinary Bladder Neoplasms

DrugsMitomycin C·Fluorouracil·Adrucil·Keytruda

Merck Sharp & Dohme LLC

Phase 3

520

L'Hospitalet de Llobregat, Valencia, Seville

2020-05-19

Active, closed

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

NCT04223596Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV

DrugBrigatinib

Fundación GECP

Phase 2

A Coruña, Alicante, Málaga, Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Las Palmas de Gran Canaria

2020-05-04

Active, closed

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

6,033

Badalona, Centelles, L'Hospitalet de Llobregat

2020-02-27

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Málaga, Pamplona, Zaragoza

2020-02-11

Active, closed

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

NCT04530318Relapsing-Remitting Multiple Sclerosis

Judit Pich

Phase 2

L'Hospitalet de Llobregat, Barcelona

2020-01-27

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Salamanca, Toledo

2020-01-16

Active, closed

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin

Takeda

Phase 3

354

L'Hospitalet de Llobregat, A Coruña, Alicante, Barcelona, Córdoba, Madrid, Valencia

2020-01-10

Active, closed

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317Non-muscle Invasive Bladder Cancer

DrugsSasanlimab·Bacillus Calmette-Guerin

Pfizer

Phase 3

1,068

Badalona, Granollers, L'Hospitalet de Llobregat, Majadahonda, Pamplona, Reus, A Coruña, Barcelona

2019-12-30

Active, closed

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206Moderate-to-Severe Atopic Dermatitis

DrugNemolizumab

Galderma R&D

Phase 3

1,700

Alicante, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona

2019-12-30

Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070Carcinoma, Non-Small-Cell Lung

DrugsMK-4830·Ifinatamab Deruxtecan·Patritumab deruxtecan·Abraxane

Merck Sharp & Dohme LLC

Phase 1/2

450

L'Hospitalet de Llobregat, Madrid

2019-12-19

Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798Carcinoma, Non-Small-Cell Lung

Merck Sharp & Dohme LLC

Observational

1,065

L'Hospitalet de Llobregat, Barcelona, Madrid

2019-12-19

Active, closed

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation

DrugsBI 1701963·TNO155·Sotorasib·Afatinib

Amgen

Phase 1

610

Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid

2019-12-17

Active, closed

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

655

L'Hospitalet de Llobregat, Majadahonda, Barcelona, Bilbao, Huelva, Málaga

2019-11-26

Active, closed

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050Myeloproliferative Neoplasm

DrugsNavitoclax·Celebrex·Celecoxib·Ruxolitinib

AbbVie

Phase 1

L'Hospitalet de Llobregat, Pamplona, Madrid

2019-11-08

Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia

DrugsCobicistat·Revumenib

Syndax Pharmaceuticals

Phase 1/2

447

L'Hospitalet de Llobregat, Seville, Valencia

2019-11-05

Active, closed

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

NCT04058756Advanced Solid Tumors

DrugSpartalizumab

Novartis Pharmaceuticals

Phase 1

120

L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2019-10-30

Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant

DrugsTulmimetostat·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

300

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell

2019-09-18

Active, closed

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma

DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed

Genmab

Phase 1/2

350

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Santiago de Compostela

2019-09-17

Active, closed

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

NCT03517137Advanced Hodgkin Lymphoma

DrugsVinblastine·Brentuximab Vedotin·Dacarbazine·Adriamycin

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

150

L'Hospitalet de Llobregat, Pamplona

2019-08-01

Active, closed

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia

DrugIbrutinib

Novartis Pharmaceuticals

Phase 1/2

217

Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia

2019-06-26

Active, closed

NADIM II: Neo-Adjuvant Immunotherapy

NCT03838159Non Small Cell Lung Cancer

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Girona, Las Palmas de Gran Canaria, A Coruña

2019-05-15

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

A Coruña, Barcelona, L'Hospitalet de Llobregat, Pamplona, Seville, Valencia

2019-05-08

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Alicante, Badalona, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santander, Seville

2019-03-21

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, San Sebastián, Santiago de Compostela, Seville

2019-03-06

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Cadiz, L'Hospitalet de Llobregat, Barcelona, Donostia / San Sebastian, Salt, Majadahonda, Pozuelo de Alarcón, El Palmar

2018-12-28

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville

2018-12-27

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Barcelona, Madrid, Seville

2018-12-17

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa

2018-12-07

Recruiting

Extension Study for the Port Delivery System With Ranibizumab (Portal)

NCT03683251Neovascular Age-Related Macular Degeneration

DrugPDS Implant with Ranibizumab

Hoffmann-La Roche

Phase 3

1,000

L'Hospitalet de Llobregat, San Cugat Del Valles, Majadahonda, Pamplona, Oviedo, Burjassot, Barcelona, Córdoba

2018-09-20

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Palma, Palma de Mallorca, L'Hospitalet de Llobregat, San Sebastian- Donostia, Santander, Badalona, Barcelona, Santiago de Compostela

2018-08-21

Active, closed

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

NCT03589222Refractory Multiple Myeloma

DrugsSelinexor·Bortezomib·Daratumumab·Dexamethasone

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Pamplona

2018-07-15

Recruiting

Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

NCT03855592Thromboembolism, Cancer

Fundación Sociedad Española de Oncologia Médica

Observational

700

Alcoy, Elche, Palma, L'Hospitalet de Llobregat, Sabadell, Sant Joan Despí, Santander, Jerez de la Frontera

2018-07-04

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643Non-small Cell Lung Cancer

DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

797

Badalona, L'Hospitalet de Llobregat, Girona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville

2018-04-24

Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)

DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide

Pfizer

Phase 1

453

L'Hospitalet de Llobregat, Castellon, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Valencia

2018-04-17

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Ferrol, L'Hospitalet de Llobregat, Sabadell, Majadahonda, Bilbao, Barcelona, Madrid, Salamanca

2018-04-09

Active, closed

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197mCRPC

Pfizer

Phase 3

1,054

Santiago de Compostela, Elche, L'Hospitalet de Llobregat, Sabadell, El Palmar, Barcelona, Madrid

2017-12-18

Active, closed

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797Breast Cancer

DrugsGiredestrant·Palbociclib

Genentech, Inc.

Phase 1

181

L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia

2017-11-24

Active, closed

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552Non-Small Cell Lung Cancer

DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib

Hoffmann-La Roche

Phase 2/3

1,000

L'Hospitalet de Llobregat, Santiago de Compostela, Pamplona, Alicante, Barcelona, Madrid, Málaga, Seville

2017-09-22

Active, closed

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

NCT03161353Breast Cancer

DrugsPerjeta·Herceptin·Tamoxifen·Pertuzumab

MedSIR

Phase 2

377

Badalona, L'Hospitalet de Llobregat, Castelló, Jaén, Málaga, Reus, A Coruña, Barcelona

2017-06-26

Recruiting

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

NCT02834884All Tumor Types

European Organisation for Research and Treatment of Cancer - EORTC

Observational

4,975

L'Hospitalet de Llobregat, Barcelona, Elche, Girona, Madrid, Málaga, Valencia, Valladolid

2017-05-03

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Majadahonda, Pamplona, A Coruña, Barcelona, Girona, Madrid

2017-04-27

Active, closed

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696Non-Hodgkin's Lymphoma

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

940

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid

2017-02-21

Active, closed

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

DrugsRamucirumab·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 2

309

L'Hospitalet de Llobregat, Barcelona, Madrid

2016-05-19

Active, closed

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516Prostatic Neoplasms

DrugsGnRH·Bicalutamide·Apalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,503

Barakaldo, Barcelona, Castellon, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Reus

2015-11-19

Recruiting

CAR-T Long Term Follow Up (LTFU) Study

NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Novartis Pharmaceuticals

Phase 3

1,105

Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2015-11-02

Active, closed

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

NCT02320435Solid Tumors

DrugsPerjeta·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

154

L'Hospitalet de Llobregat, Santander, San Cristóbal de La Laguna, Bilbao, Barcelona, Valencia

2015-02-02

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631Non Small Cell Lung Cancer

DrugsErlotinib·Abemaciclib

Eli Lilly and Company

Phase 3

453

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia

2014-10-03

Active, closed

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

DrugIbrutinib

Janssen Research & Development, LLC

Phase 3

539

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca

2013-09-09

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

A Coruña, Córdoba, Elche, Girona, Granada, L'Hospitalet de Llobregat, Madrid, Málaga

2012-01

Active, closed

Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

NCT01558921Rectal Cancer

University Medical Center Groningen

Phase 3

920

Barcelona, L'Hospitalet de Llobregat, Valencia

2011-06-21

Active, closed

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

NCT01924819Gastric Cancer

DrugsEpirubicin·Leucovorin·Adrucil·Docetaxel

Australasian Gastro-Intestinal Trials Group

Phase 2/3

574

L'Hospitalet de Llobregat, Badalona, Barcelona, Valencia

2009-09

Active, closed

Effectiveness of Localized Prostate Cancer Treatments

NCT01492751Prostate Cancer

Fundacion IMIM

Observational

500

Hospitalet Llobregat,, L'Hospitalet de Llobregat, Sant Cugat del Vallès, San Sebastián, A Coruña, Barcelona, Madrid, Málaga

2003-04

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

A Coruña, Barcelona, Barakaldo, L'Hospitalet de Llobregat, Vigo, Tarragona

2001-07-31

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/l-hospitalet-de-llobregat

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 446 of those studies with a site in L'Hospitalet de Llobregat.

How many clinical trials are recruiting in L'Hospitalet de Llobregat?

215 of the 446 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 16 have not yet opened recruitment, 206 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (L'Hospitalet de Llobregat), 446 studies
Phase	Studies	Recruiting	Share
Phase 3	191	86	42.8%
Phase 2	72	26	16.1%
Observational	51	30	11.4%
Not applicable	48	31	10.8%
Phase 1/2	39	23	8.7%
Phase 1	29	10	6.5%
Phase 2/3	9	4	2%
Phase 4	7	5	1.6%

Most active sponsors

Lead sponsors with the most studies (L'Hospitalet de Llobregat)
Lead sponsor	Studies	Recruiting
AstraZeneca	39	22
Merck Sharp & Dohme LLC	35	21
Novartis Pharmaceuticals	30	12
Hospital Universitari de Bellvitge	27	13
Pfizer	19	8
Hoffmann-La Roche	17	5
AbbVie	14	2
Janssen Research & Development, LLC	12	3
Boehringer Ingelheim	10	6
Fundación EPIC	9	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.